RAPGEF1 and B-cell non-Hodgkin lymphoma: To achieve this, we introduced the activating Y564H point mutation into the Rapgef1 gene [38] in the A20 mouse B-cell lymphoma line using the CRISPR/Cas9 gene editing system with HDR.